

Salutation	First Name	Last Name	City	Country	Type of Relation	Other Relationship	Company	Therapeutic product
Mr.	ABASS	ABDUL-KARIM	Kumasi	Ghana				
Ms.	Fariyo	Abdullahi	London	United Kingdom				
Dr.	Salahuddin	Ahmed	Dhaka	Bangladesh				
Prof.	Jingwen	Ai	Shanghai	China				
Ms.	Oluwasefunmi	Akeju	Oxford	United Kingdom				
Dr.	Victor	Akelo	Kisumu	Kenya				
Mr.	Eniola	Akoledowo	Ibadan	Nigeria				

Mr.	Aliyu	Aliyu	Kano	Nigeria				
Dr.	Sónia	Almeida	Oeiras	Portugal				
Dr.	AHMED	ALMEZAINÉ	TANTA	Egypt				
Mr.	Vítor	Alves	São Paulo	Brazil				
Dr.	Carmen	Ardanuy	L'Hospitale t de Llobregat	Spain				
Dr.	Shams	Arifeen	Dhaka	Bangladesh				
Dr.	Zein	Assad	Paris	France				
Dr.	Vicky	Baillie	Johannesb urg	South Africa				

Ms.	Lotte	Bak	Hillerød	Denmark				
Prof.	Quique	Bassat	Barcelona	Spain				
Dr.	Sophie	Belman	Barcelona	Spain				
Prof.	Thomas	Benfield	Hvidovre	Denmark				
Dr.	Jacob Dag	Berild	Oslo	Norway				
Mr.	Jens Magnus	Bernth Jensen	Aarhus	Denmark				
Dr.	Michael	Binks	Darwin	Australia				PHID-CV10 (Synflorix) was administered in pregnancy under ethics-approved clinical trial conditions, outside routine indications.
Prof.	Debby	Bogaert	Edinburgh	United Kingdom	Honoraria/ Expenses		OM Pharma	

Dr.	Elsa	Bou Ghanem	Buffalo	United States of America				
Ms.	Sanjita	Brito Mutunayagam	Oxford	United Kingdom	Funded Research		Pfizer Inc	
Mr.	Hugh	Brown	Melbourne	Australia				
Prof.	Angela B	Brueggemann	Oxford	United Kingdom	Funded Research		Merck Sharp & Dohme	
Dr.	Thomas	Cherian	Versoix	Switzerland				
Dr.	Tarsizio	Chikaonda	Blantyre	Malawi				
Dr.	Mohammad Jobayer	Chisti	Dhaka	Bangladesh				
Dr.	Sopio	Chochua	Atlanta	United States of America				

Dr.	Yoon Hong	Choi	London	United Kingdom				
Ms.	Dewi	Christina	Jakarta	Indonesia				
Dr.	Catia	Cilloniz	Barcelona	Spain				
Dr.	Adam	Cohen	Atlanta	United States of America				
Dr.	Matthew	Coldiron	London	United Kingdom				
Dr.	Mary	Corcoran	Dublin	Ireland	Funded Research		Pfizer	
Dr.	Andrew	Cox	Rochester	United States of America				

Dr.	Amelieke	Cremers	Lausanne	Switzerland	Consultant/ Advisory Board		Merck MSD	15 antibiotics with known mode of actions were used in in-vitro experiments to understand the antimicrobial pressures present in human specimens. Not for treatment purposes.
Dr.	Nicholas	Croucher	Cambridge	United Kingdom	Consultant/ Advisory Board		Merck/MSD	
Ms.	Lize	Cuypers	Leuven	Belgium	Other	Travel support for ISPPD-13	MSD	
Prof.	Ron	Dagan	Beer-Sheva	Israel	Funded Research		Pfizer	
Dr.	Wa Ode Dwi	Daningrat	Oxford	United Kingdom				
Prof.	Marien I.	de Jonge	Nijmegen	Netherlands				
Mr.	David	de Vos	Leiden	Netherlands				

Prof.	Stefanie	Desmet	Leuven	Belgium	Consultant/ Advisory Board		Merck	
Prof.	David	Dockrell	Edinburgh	United Kingdom				
Dr.	Klara	Doherty	Liverpool	United Kingdom				
Dr.	Vannida	Douangbough a	Vientiane (prefecture)	Laos				
Dr.	Mignon	du Plessis	Johannesb urg	South Africa				
Dr.	Eileen M.	Dunne	Collegevill e	United States of America	Employee		Pfizer	
Dr.	vegard	eldholm	Oslo	Norway				
Prof.	Olivier	Epaulard	Grenoble	France				

Dr.	Giuseppe	Ercoli	London	United Kingdom				
Dr.	Helle	Eriksen	Herlev	Denmark				
Dr.	Markus	Fally	Roskilde	Denmark				
Dr.	Nicholas	Fancourt	Sydney	Australia				Clinical trial of Pneumosil in the care of children recovering from severe acute malnutrition
Prof.	Daniela	Ferreira	Oxford	United Kingdom				
Ms.	Katherine	Gallagher	London	United Kingdom				
Dr.	Feroze	Ganaie	Birmingham	United States of America				
Mr.	Jeremiah	Ganyo	Navrongo	Ghana				

Mr.	Ryan	Gierke	Atlanta	United States of America				
Dr.	Rebecca A.	Gladstone	Oslo	Norway				
Prof.	David	Goldblatt	London	United Kingdom	Other	My UCL laboratory is in receipt of funding for contract research undertaken on behalf of pneumococcal vaccine manufacturers.	Sanofi Pasteur, GSK and Serum Institute of India	
Ms.	Rahma	Golicha	NAIROBI	Kenya				
Mr.	Geard	Gomez Heredia	Bogota	Colombia				
Dr.	Aida	González-Díaz	Barcelona	Spain				
Mr.	Simon	Gyimah	POTSDAM	United States of America				
Dr.	Rana	Hajjeh	Atlanta	United States of America				

Dr.	Oliver	Hamilton	Liverpool	United Kingdom	Funded Research		Pfizer	
Mr.	Sven	Hammerschmidt	Greifswald	Germany				
Dr.	Bill	Hanage	Boston	United States of America	Consultant/ Advisory Board		Merck Vaccines	
Dr.	Zitta Barrella	Harboe	Copenhagen	Denmark				
Dr.	Whitney	Hartlage	Seattle	United States of America				
Dr.	William	Hausdorff	Washington	United States of America	Royalties/Patent		Wyeth (Pfizer): I am co-inventor of several patents related to PCV13, but since I was a Wyeth employee at the time receive no royalties as per industry practice	

Ms.	Abigail	Her	New Haven	United States of America				
Mrs.	Laura	Holler	Boca Raton	United States of America	Employee		ADMA Biologics	
Dr.	Samuel	Horsfield	Cambridge	United Kingdom				
Mr.	Hanwen	Hou	Melbourne	Australia				
Dr.	Dennis	Hoving	Leiden	Netherlands				
Prof.	Federico	Iovino	Stockholm	Sweden	Funded Research		Therakind	
Mr.	Md Shfiqul	Islam	Dhaka	Bangladesh				
Dr.	Alane	Izu	Johannesburg	South Africa				

Ms.	Vinita	Jagannath	Rahway	United States of America	Employee		Merck & Co., Inc.	Investigational use of V116 in pediatric population
Mr.	Wujun	Jiang	Suzhou	China				
Dr.	Simon	Jochems	Leiden	Netherlands	Honoraria/ Expenses		GSK	
Dr.	Isik Somuncu	Johansen	Odense	Denmark				
Dr.	Kelly	Johnson	Rahway	United States of America				
Dr.	Ximena	JUAREZ	CIUDAD DE BUENOS AIRES	Argentina				
Dr.	Akuzike	Kalizang'oma	Blantyre	Malawi				
Ms.	Isis	Kanevsky	Pearl River	United States of America	Employee		Pfizer Inc	

Dr.	Melina	Kang'oma	Blantyre 3	Malawi				
Mr.	Nitesh	Karna	Dharan	Nepal				
Mrs.	Dian	Karssen	Utrecht	Netherlands				
Ms.	Thokozani	Kayembe	Blantyre	Malawi				
Prof.	Keith	Klugman	Seattle	United States of America				
Prof.	Maria	Knoll	Baltimore	United States of America	Consultant/ Advisory Board		Inventprise	
Dr.	Miwako	Kobayashi	Atlanta	United States of America				
Mr.	Sumit	Kumar	Dundee	United Kingdom				

Mr.	Michael	Kutte	Yola	Nigeria				
Dr.	Brenda	Kwambana-Adams	Blantyre	Malawi	Funded Research		Sanofi	
Dr.	Shamez	Ladhani	London	United Kingdom				I will be talking about the UK PCV13 immunisation programme which is given as an off-license 1+1 schedule
Dr.	Rotem	Lapidot	Haifa	Israel	Funded Research		Pfizer	
Dr.	Carsten	Larsen	Hinnerup	Denmark	Employee		Sanofi	
Dr.	MARIA	LATTANZI	Siena	Italy	Stock Options		GSK	
Mr.	Antidius	Laurian	Cape Town	South Africa				
Dr.	Joseph	Lewnard	Berkeley	United States of America	Honoraria/ Expenses		Pfizer	

Dr.	Gareth	Lipunga	Blantyre	Malawi				
Dr.	Stephanie	Lo	Hinxton	United Kingdom				
Miss	Frederikke	Lomholt	Copenhagen	Denmark				
Prof.	Grant	Mackenzie	Basse	Gambia	Consultant/ Advisory Board		Pfizer	PCV 2 dose schedule
Prof.	Shabir	Madhi	Johannesburg	South Africa	Funded Research		Gates Foundation	
Mr.	Rick	Malley	Boston	United States of America	Consultant/ Advisory Board		Limmunech	
Ms.	Hannah Czarina	Manoy	CITY OF MANILA	Philippines				
Ms.	Aur�lie	Maurin	Paris	France				

Ms.	Mphatso	Mayuni	Blantyre	Malawi				
Dr.	Natalie	Mazur	Utrecht	Netherlands				
Mr.	EMMANUEL	MCHOMA	Blantyre	Malawi				
Dr.	Kate	Mellor	Cambridge	United Kingdom				
Dr.	Zahid	Memon	Karachi	Pakistan				
Prof.	Elena	Mitsi	Oxford	United Kingdom				
Dr.	Susana	Morais	Oeiras	Portugal				
Dr.	Jarrod	Mousa	Tallahassee	United States of America				

Dr.	Peter	Mueller	Rahway	United States of America	Employee		MSD	
Dr.	Eleanor	Neal	Parkville	Australia				Discussion of reduced-dose (1p+1) pneumococcal conjugate vaccine schedules
Dr.	Catram	Nguyen	Melbourne	Australia	Funded Research		Merck Investigator Study Program	
Mr.	Aryan	Nikhab	London	United Kingdom				
Dr.	Muhammad Imran	Nisar	Karachi	Pakistan	Consultant/ Advisory Board		Pfizer Inc	
Ms.	Eunice	Njuguna	Kilifi	Kenya				
Mr.	Charles	Nkhata	Blantyre	Malawi				
Prof.	Oliver	Odikamnorro	Abakaliki	Nigeria				

Ms.	Shahin	Oftadeh	Sydney	Australia				
Dr.	Courtney	Olwagen	Johannesb urg	South Africa				
Ms.	Olawumi	Onaolapo	Ibadan	Nigeria				
Prof.	Carlos	Orihuela	Birmingha m	United States of America				
Mrs.	Marie	Ørntoft	Hillerød	Denmark				
Dr.	Ioannis	Passaris	Brussels	Belgium				
Dr.	Dr Swati	PATIL	Latur	India				
Ms.	Covadonga	Pérez-García	Madrid	Spain				

Dr.	Stephanie	Perniciaro	New Haven	United States of America	Employee		Pfizer	
Dr.	Alicia	Quach	Melbourne	Australia				
Dr.	Billy	Quilty	Berlin	Germany				Synflorix PCV10
Dr.	Antonio	Quispe	Lima	Peru				
Mr.	Md. Hafizur	Rahman	Dhaka	Bangladesh				
Prof.	Mário	Ramirez	Lisbon	Portugal	Consultant/ Advisory Board		Pfizer	
Mr.	Linus	Rechsteiner	Bern	Switzerland				
Prof.	Gili	Regev-Yochay	Tel-Aviv	Israel				

Dr.	Joon Haeng	Rhee	Hwasun	Korea, Republic of				Product under development
Dr.	Ismar	Rivera-Olivero	Quito	Ecuador				
Dr.	Gail	Rodgers	Seattle	United States of America				
Mr.	Graeme	Rooney	Durham	United Kingdom				
Prof.	Fiona	Russell	MELBOUR NE	Australia				
Dr.	Charu	Sabharwal	Pearl River	United States of America	Other	Employee and Stock Options	Pfizer	Pfizer PCV25
Dr.	Senjuti	Saha	Dhaka	Bangladesh				
Dr.	Raquel	Sa-Leao	Oeiras	Portugal	Consultant/ Advisory Board		MSD	

Dr.	Maria Leonor	Sarno Oliveira	São Paulo	Brazil				
Prof.	Catherine	Satzke	Melbourne	Australia	Honoraria/ Expenses		MSD/Merck	
Dr.	Julio	Sempere	Madrid	Spain				
Dr.	Cristian	Serrano-Mayorga	Chia	Colombia	Consultant/ Advisory Board		MSD (Merck Sharp and Dhome) Colombia	
Ms.	Afsana	Shammi	Dhaka	Bangladesh				
Dr.	Reiko	Shimbashi	Tokyo	Japan				
Ms.	Hannah	Shrader	Oxford	United Kingdom				
Ms.	Paige	Skoko	Melbourne	Australia				

Mr.	Hans-Christian	Slotved	Roskilde	Denmark	Funded Research		Pfizer	
Ms.	Sarah	Smith	Westmead	Australia				
Dr.	Catherine	Sutcliffe	Baltimore	United States of America				
Mrs	Charlotte	Sværke Jørgensen	Copenhagen	Denmark				
Dr.	Joshua	Szanyi	Melbourne	Australia	Funded Research		Moderna, Inc.	
Dr.	Deus	Thindwa	New Haven	United States of America				
Dr.	Claudia	Trappetti	Bologna	Italy				
Dr.	Krzysztof	Trzeciński	Utrecht	Netherlands	Consultant/ Advisory Board		Merck Sharp & Dohme	

Prof	Paul	Turner	Siem Reap	Cambodia				
Dr.	Britta	Urban	Oxford	United Kingdom				
Dr.	Verónica	Urdaneta-Páez	Orlando	United States of America				
Dr.	Kevin	van Zandvoort	London	United Kingdom				I will present results that includes the effect of off-label use of the Pneumosil vaccine in children aged 2-4 years of age in a camp for displaced people. Pneumosil is only WHO pre-qualified for children <2 years.
Mrs	Rosemol	Varghese	Vellore	India				
Dr.	Valerie M.	Vaughn	Salt Lake City	United States of America	Consultant/ Advisory Board		Danaher	
Dr.	Jennifer	Verani	Atlanta	United States of America				

Dr.	Jorge	Vidal	Jackson	United States of America				
Dr.	Claire	von Mollendorf	Melbourne	Australia				
Mr.	Amusa	Wamawobe	BLANTYRE CENTRAL	Malawi				
Ms.	Jasmine	Waters	Sydney	Australia				
Dr.	Daniel	Weinberger	New Haven	United States of America	Consultant/ Advisory Board		Pfizer	
Prof.	Jeffrey	Weiser	New York	United States of America	Consultant/ Advisory Board		Merck	
Dr.	Cynthia	Whitney	Decatur	United States of America				
Ms.	Anabelle	Wong	London	United Kingdom	Honoraria/ Expenses		Vaxcyte Inc.	

Dr.	Xueqing	Wu	Hangzhou	China				
Dr.	Baleng Mahama	Wutor	Decatur	United States of America				
Dr.	Inci	Yildirim	New Haven	United States of America				